Literature DB >> 24918341

Intrathecal infusion of BMAA induces selective motor neuron damage and astrogliosis in the ventral horn of the spinal cord.

Hong Z Yin1, Stephen Yu1, Cheng-I Hsu1, Joe Liu1, Allan Acab1, Richard Wu1, Anna Tao1, Benjamin J Chiang1, John H Weiss2.   

Abstract

The neurotoxin beta-N-methylamino-l-alanine (BMAA) was first identified as a "toxin of interest" in regard to the amyotrophic lateral sclerosis-Parkinsonism Dementia Complex of Guam (ALS/PDC); studies in recent years highlighting widespread environmental sources of BMAA exposure and providing new clues to toxic mechanisms have suggested possible relevance to sporadic ALS as well. However, despite clear evidence of uptake into tissues and a range of toxic effects in cells and animals, an animal model in which BMAA induces a neurodegenerative picture resembling ALS is lacking, possibly in part reflecting limited understanding of critical factors pertaining to its absorption, biodistribution and metabolism. To bypass some of these issues and ensure delivery to a key site of disease pathology, we examined effects of prolonged (30day) intrathecal infusion in wild type (WT) rats, and rats harboring the familial ALS associated G93A SOD1 mutation, over an age range (80±2 to 110±2days) during which the G93A rats are developing disease pathology yet remain asymptomatic. The BMAA exposures induced changes that in many ways resemble those seen in the G93A rats, with degenerative changes in ventral horn motor neurons (MNs) with relatively little dorsal horn pathology, marked ventral horn astrogliosis and increased 3-nitrotyrosine labeling in and surrounding MNs, a loss of labeling for the astrocytic glutamate transporter, GLT-1, surrounding MNs, and mild accumulation and aggregation of TDP-43 in the cytosol of some injured and degenerating MNs. Thus, prolonged intrathecal infusion of BMAA can reproduce a picture in spinal cord incorporating many of the pathological hallmarks of diverse forms of human ALS, including substantial restriction of overt pathological changes to the ventral horn, consistent with the possibility that environmental BMAA exposure could be a risk factor and/or contributor to some human disease.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24918341      PMCID: PMC4194249          DOI: 10.1016/j.expneurol.2014.06.003

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  66 in total

1.  Marked synergism between mutant SOD1 and glutamate transport inhibition in the induction of motor neuronal degeneration in spinal cord slice cultures.

Authors:  Hong Z Yin; John H Weiss
Journal:  Brain Res       Date:  2012-02-09       Impact factor: 3.252

2.  AMPA exposures induce mitochondrial Ca(2+) overload and ROS generation in spinal motor neurons in vitro.

Authors:  S G Carriedo; S L Sensi; H Z Yin; J H Weiss
Journal:  J Neurosci       Date:  2000-01-01       Impact factor: 6.167

3.  Cyanobacterial Blooms and the Occurrence of the neurotoxin beta-N-methylamino-L-alanine (BMAA) in South Florida Aquatic Food Webs.

Authors:  Larry E Brand; John Pablo; Angela Compton; Neil Hammerschlag; Deborah C Mash
Journal:  Harmful Algae       Date:  2010-09-01       Impact factor: 4.273

Review 4.  An appraisal of the neurotoxicity of cycad and the etiology of amyotrophic lateral sclerosis on Guam.

Authors:  L T Kurland
Journal:  Fed Proc       Date:  1972 Sep-Oct

5.  Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis.

Authors:  J D Rothstein; M Van Kammen; A I Levey; L J Martin; R W Kuncl
Journal:  Ann Neurol       Date:  1995-07       Impact factor: 10.422

6.  Occurrence of beta-methylamino-l-alanine (BMAA) in ALS/PDC patients from Guam.

Authors:  S J Murch; P A Cox; S A Banack; J C Steele; O W Sacks
Journal:  Acta Neurol Scand       Date:  2004-10       Impact factor: 3.209

7.  Parvalbumin is a marker of ALS-resistant motor neurons.

Authors:  J L Elliott; W D Snider
Journal:  Neuroreport       Date:  1995-02-15       Impact factor: 1.837

8.  Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS.

Authors:  Janice Robertson; Teresa Sanelli; Shangxi Xiao; Wencheng Yang; Patrick Horne; Robert Hammond; Erik P Pioro; Michael J Strong
Journal:  Neurosci Lett       Date:  2007-04-08       Impact factor: 3.046

Review 9.  Does α-amino-β-methylaminopropionic acid (BMAA) play a role in neurodegeneration?

Authors:  Alexander S Chiu; Michelle M Gehringer; Jeffrey H Welch; Brett A Neilan
Journal:  Int J Environ Res Public Health       Date:  2011-09-16       Impact factor: 3.390

10.  The non-protein amino acid BMAA is misincorporated into human proteins in place of L-serine causing protein misfolding and aggregation.

Authors:  Rachael Anne Dunlop; Paul Alan Cox; Sandra Anne Banack; Kenneth John Rodgers
Journal:  PLoS One       Date:  2013-09-25       Impact factor: 3.240

View more
  18 in total

1.  Creating a Simian Model of Guam ALS/PDC Which Reflects Chamorro Lifetime BMAA Exposures.

Authors:  Sandra Anne Banack; Paul Alan Cox
Journal:  Neurotox Res       Date:  2017-05-06       Impact factor: 3.911

Review 2.  Potential Environmental Factors in Amyotrophic Lateral Sclerosis.

Authors:  Björn Oskarsson; D Kevin Horton; Hiroshi Mitsumoto
Journal:  Neurol Clin       Date:  2015-11       Impact factor: 3.806

3.  Intravenous injection of l-BMAA induces a rat model with comprehensive characteristics of amyotrophic lateral sclerosis/Parkinson-dementia complex.

Authors:  Ke-Wei Tian; Hong Jiang; Bei-Bei Wang; Fan Zhang; Shu Han
Journal:  Toxicol Res (Camb)       Date:  2015-11-10       Impact factor: 3.524

4.  Assessing Environmental Exposure to β-N-Methylamino-L-Alanine (BMAA) in Complex Sample Matrices: a Comparison of the Three Most Popular LC-MS/MS Methods.

Authors:  Teesha C Baker; Fiona J M Tymm; Susan J Murch
Journal:  Neurotox Res       Date:  2017-06-22       Impact factor: 3.911

Review 5.  Neuropathological Mechanisms of β-N-Methylamino-L-Alanine (BMAA) with a Focus on Iron Overload and Ferroptosis.

Authors:  Hamed Kazemi Shariat Panahi; Mona Dehhaghi; Benjamin Heng; Darius J R Lane; Ashley I Bush; Gilles J Guillemin; Vanessa X Tan
Journal:  Neurotox Res       Date:  2022-01-13       Impact factor: 3.911

Review 6.  Modelling amyotrophic lateral sclerosis in rodents.

Authors:  Tiffany W Todd; Leonard Petrucelli
Journal:  Nat Rev Neurosci       Date:  2022-03-08       Impact factor: 34.870

7.  Identifying aerosolized cyanobacteria in the human respiratory tract: A proposed mechanism for cyanotoxin-associated diseases.

Authors:  Dominic N Facciponte; Matthew W Bough; Darius Seidler; James L Carroll; Alix Ashare; Angeline S Andrew; Gregory J Tsongalis; Louis J Vaickus; Patricia L Henegan; Tanya H Butt; Elijah W Stommel
Journal:  Sci Total Environ       Date:  2018-07-20       Impact factor: 7.963

8.  Is Exposure to BMAA a Risk Factor for Neurodegenerative Diseases? A Response to a Critical Review of the BMAA Hypothesis.

Authors:  Dunlop Ra; Banack Sa; Bishop Sl; Metcalf Js; Murch Sj; Davis DA; Stommel Ew; Karlsson O; Brittebo Eb; Chatziefthimiou Ad; Tan Vx; Guillemin Gg; Cox Pa; Mash Dc; Bradley Wg
Journal:  Neurotox Res       Date:  2021-02-06       Impact factor: 3.911

9.  BMAA, Neurodegeneration, and Neuroprotection.

Authors:  Paul Alan Cox
Journal:  Neurotox Res       Date:  2020-11-16       Impact factor: 3.911

10.  Dietary exposure to an environmental toxin triggers neurofibrillary tangles and amyloid deposits in the brain.

Authors:  Paul Alan Cox; David A Davis; Deborah C Mash; James S Metcalf; Sandra Anne Banack
Journal:  Proc Biol Sci       Date:  2016-01-27       Impact factor: 5.349

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.